Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
Public ClinicalTrials.gov record NCT01049984. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease
Study identification
- NCT ID
- NCT01049984
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Teva Neuroscience, Inc.
- Industry
- Enrollment
- 328 participants
Conditions and interventions
Conditions
Interventions
- Rasagiline Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2009
- Primary completion
- Sep 30, 2012
- Completion
- Sep 30, 2012
- Last update posted
- May 19, 2016
2009 – 2012
United States locations
- U.S. sites
- 58
- U.S. states
- 30
- U.S. cities
- 54
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 34 | Phoenix | Arizona | — | — |
| Teva Investigational Site 42 | Sun City | Arizona | — | — |
| Teva Investigational Site 15 | Fountain Valley | California | — | — |
| Teva Investigational Site 19 | Fresno | California | — | — |
| Teva Investigational Site 36 | Fresno | California | — | — |
| Teva Investigational Site 04 | La Jolla | California | — | — |
| Teva Investigational Site 29 | Reseda | California | — | — |
| Teva Investigational Site 69 | San Francisco | California | — | — |
| Teva Investigational Site 02 | Sunnyvale | California | — | — |
| Teva Investigational Site 43 | Ventura | California | — | — |
| Teva Investigational Site 44 | Fairfield | Connecticut | — | — |
| Teva Investigational Site 07 | Manchester | Connecticut | — | — |
| Teva Investigational Site 25 | Newark | Delaware | — | — |
| Teva Investigative Site 63 | Atlantis | Florida | — | — |
| Teva Investigational Site 30 | Boca Raton | Florida | — | — |
| Teva Investigational Site 13 | Clearwater | Florida | — | — |
| Teva Investigational Site 70 | Sunrise | Florida | — | — |
| Teva Investigational Site 41 | Tampa | Florida | — | — |
| Teva Investigational Site 61 | Vero Beach | Florida | — | — |
| Teva Investigational Site 01 | Decatur | Georgia | — | — |
| Teva Investigational Site 58 | Boise | Idaho | — | — |
| Teva Investigational Site 49 | Glenview | Illinois | — | — |
| Teva Investigational Site 23 | Peoria | Illinois | — | — |
| Teva Investigational Site 47 | Indianapolis | Indiana | — | — |
| Teva Investigational Site 67 | Indianapolis | Indiana | — | — |
| Teva Investigational Site 76 | Indianapolis | Indiana | — | — |
| Teva Investigational Site 55 | Des Moines | Iowa | — | — |
| Teva Investigational Site 17 | Lexington | Kentucky | — | — |
| Teva Investigational Site 27 | Paducah | Kentucky | — | — |
| Teva Investigational Site 56 | Scarborough | Maine | — | — |
| Teva Investigational Site 62 | Elkridge | Maryland | — | — |
| Teva Investigational Site 51 | Springfield | Massachusetts | — | — |
| Teva Investigational Site 11 | Detroit | Michigan | — | — |
| Teva Investigational Site 33 | West Bloomfield | Michigan | — | — |
| Teva Investigational Site 39 | Golden Valley | Minnesota | — | — |
| Teva Investigational Site 22 | St Louis | Missouri | — | — |
| Teva Investigational Site 08 | Great Falls | Montana | — | — |
| Teva Investigational Site 59 | Missoula | Montana | — | — |
| Teva Investigational Site 60 | Las Vegas | Nevada | — | — |
| Teva Investigational Site 14 | Somerset | New Jersey | — | — |
| Teva Investigational Site 03 | Commack | New York | — | — |
| Teva Investigational Site 38 | Plainview | New York | — | — |
| Teva Investigational Site 05 | Asheville | North Carolina | — | — |
| Teva Investigational Site 31 | Charlotte | North Carolina | — | — |
| Teva Investigational Site 28 | Raleigh | North Carolina | — | — |
| Teva Investigational Site 26 | Fargo | North Dakota | — | — |
| Teva Investigational Site 35 | Cincinnati | Ohio | — | — |
| Teva Investigational Site 68 | Cincinnati | Ohio | — | — |
| Teva Investigational Site 64 | Tulsa | Oklahoma | — | — |
| Teva Investigational Site 21 | Medford | Oregon | — | — |
| Teva Investigational Site 40 | Portland | Oregon | — | — |
| Teva Investigative Site 65 | Cordova | Tennessee | — | — |
| Teva Investigational Site 71 | Brownwood | Texas | — | — |
| Teva Investigational Site 18 | San Antonio | Texas | — | — |
| Teva Investigational Site 32 | Temple | Texas | — | — |
| Teva Investigational Site 09 | Richmond | Virginia | — | — |
| Teva Investigational Site 46 | Virginia Beach | Virginia | — | — |
| Teva Investigational Site 77 | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01049984, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 19, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01049984 live on ClinicalTrials.gov.